Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study ...

Alliance News 16 June, 2023 | 7:51AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

The Hong Kong-based cancer and immunological diseases treatment developer said the publication shows how the treatment with fruquintinib reduced the risk of death by 34% in CRC patients.

This comes after Hutchmed announced on Thursday that its marketing authorisation application for fruquintinib, alongside Tokyo-based Takeda, was validated and accepted by the European Medicines Agency.

Fruiquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Shares in Hutchmed were up 2.9% at 213.00 pence each in London on Friday morning, while shares in Takeda had closed up 0.8% at JPY4,572.00 each in Tokyo.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
HUTCHMED (China) Ltd 350.00 GBX -0.57 -
Takeda Pharmaceutical Co Ltd 4,102.00 JPY -0.65

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures